Dinesh Khanna, Frank Kramer, Josef Höfler, Mercedeh Ghadessi, Peter Sandner, Yannick Allanore, Christopher P Denton, Masataka Kuwana, Marco Matucci-Cerinic, Janet E Pope, Tatsuya Atsumi, Radim Bečvář, László Czirják, Ellen De Langhe, Eric Hachulla, Tomonori Ishii, Osamu Ishikawa, Sindhu R Johnson, Valeria Riccieri, Elena Schiopu, Richard M Silver, Vanessa Smith, Chiara Stagnaro, Virginia Steen, Wendy Stevens, Gabriella Szücs, Marie-Elise Truchetet, Melanie Wosnitza, Oliver Distler
OBJECTIVE: To examine disease and target engagement biomarkers in the RISE-SSc trial of riociguat in early diffuse cutaneous systemic sclerosis and their potential to predict the response to treatment. METHODS: Patients were randomized to riociguat (n = 60) or placebo (n = 61) for 52 weeks. Skin biopsies and plasma/serum samples were obtained at baseline and week 14. Plasma cyclic guanosine monophosphate (cGMP) was assessed using radio-immunoassay...
March 9, 2024: Rheumatology